2025 H2 -tulosraportti
124 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenMy assessment, but no investment recommendation. 1. Start of production A1 shortly (at the latest by the end of Q3). Share price increase 2. New contracts are coming and potential extensions of existing ones. Customers report good Phase 2 results. 2026-2027. Share price increase 3. Plans for A2 and AGlobal will be launched with partners in USA and Asia. At the same time, customers are nearing completion of Phase 3 studies and approved treatments. 2027-2029. Share price increase 4. Thor has become an international stable supplier of isotopes for first-class cancer treatment for a range of cancer diseases. 2030. Stable dividend machine with good return.
I actually think exactly the same. That's how I see it too. Good summary of a possible future.
·22 t sittenAssessment of Thor Medical ASA based on Ludwig von Mises’ economic principles: Thor Medical ASA (TRMED.OL) is a Norwegian listed company that produces alpha particle emitters (Th-228, Ra-224, Pb-212) for targeted cancer therapy. The technology utilizes natural thorium decay without reactors/cyclotrons with high efficiency, lower costs, and a better environmental profile than current players. Pilot production at Herøya since 2024; AlphaOne facility under construction (operation 2026). Several supply agreements (order book ~850 mill. NOK). 2025: Revenue ~0.8 mill. NOK, loss ~58 mill. NOK, cash ~181 mill. NOK, financed mainly via equity + drawn NOK 90 mill. loan from Innovasjon Norge. Strong management with pharma, industry, and nuclear expertise.  Mises’ core principles (Human Action et al.): Methodological individualism, subjective value, entrepreneurship under uncertainty, profit/loss as signals, voluntary exchange, private property – against state intervention, regulation, and artificial credit that distorts prices and creates malinvestment such as e.g. Morrow Batteries. Positive aspects (good correspondence): • Entrepreneurship: Classic discovery of opportunity – new separation technology solves isotope bottleneck in growing TAT market. Patents applied for (Mises supported IP protection for innovation). • Market mechanism: Voluntary contracts with private customers (Telix, ARTBIO et al.) show consumer sovereignty and value creation via prices. • Profit motive: Goal of profitable scaling; the stock market prices future potential (high expectations for hundreds of millions of NOK in annual revenue at full operation). Private initiative from Scatec-inspired owners. Critical aspects (interventionist deviations): • State funding: The Innovasjon Norge loan is typical industrial policy Mises criticized – subsidizes risk, distorts capital allocation, and can lead to malinvestment financed by taxpayers. • Regulation: Heavy nuclear/pharmaceutical regulation (DSA, GMP) raises barriers and costs, replaces market assessment with bureaucracy. • Healthcare: Third-party payers (public reimbursement) distort demand further down the chain. Conclusion: Thor Medical exemplifies Misesian entrepreneurship in a distorted market – innovative, market-oriented, and potentially value-creating. Success depends on whether real profit from customers confirms economic sustainability without persistent state support. In a pure laissez-faire system (minimal state, sound money), such innovation would have flourished faster. The company is promising, but affected by interventionism which makes pure calculation more difficult.
Ludwig von Mises is spinning so fast in his grave that he will soon produce electricity for A1 at Herøya....
·1 päivä sittenSecurities funds KLP and Storebrand Indeks have started gradually buying up. Perhaps there will be a little better development for the Thor share going forward?Yes it is small, based on the volumes that are currently trading. Where do you find info about this`?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
124 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenMy assessment, but no investment recommendation. 1. Start of production A1 shortly (at the latest by the end of Q3). Share price increase 2. New contracts are coming and potential extensions of existing ones. Customers report good Phase 2 results. 2026-2027. Share price increase 3. Plans for A2 and AGlobal will be launched with partners in USA and Asia. At the same time, customers are nearing completion of Phase 3 studies and approved treatments. 2027-2029. Share price increase 4. Thor has become an international stable supplier of isotopes for first-class cancer treatment for a range of cancer diseases. 2030. Stable dividend machine with good return.I actually think exactly the same. That's how I see it too. Good summary of a possible future.
- ·22 t sittenAssessment of Thor Medical ASA based on Ludwig von Mises’ economic principles: Thor Medical ASA (TRMED.OL) is a Norwegian listed company that produces alpha particle emitters (Th-228, Ra-224, Pb-212) for targeted cancer therapy. The technology utilizes natural thorium decay without reactors/cyclotrons with high efficiency, lower costs, and a better environmental profile than current players. Pilot production at Herøya since 2024; AlphaOne facility under construction (operation 2026). Several supply agreements (order book ~850 mill. NOK). 2025: Revenue ~0.8 mill. NOK, loss ~58 mill. NOK, cash ~181 mill. NOK, financed mainly via equity + drawn NOK 90 mill. loan from Innovasjon Norge. Strong management with pharma, industry, and nuclear expertise.  Mises’ core principles (Human Action et al.): Methodological individualism, subjective value, entrepreneurship under uncertainty, profit/loss as signals, voluntary exchange, private property – against state intervention, regulation, and artificial credit that distorts prices and creates malinvestment such as e.g. Morrow Batteries. Positive aspects (good correspondence): • Entrepreneurship: Classic discovery of opportunity – new separation technology solves isotope bottleneck in growing TAT market. Patents applied for (Mises supported IP protection for innovation). • Market mechanism: Voluntary contracts with private customers (Telix, ARTBIO et al.) show consumer sovereignty and value creation via prices. • Profit motive: Goal of profitable scaling; the stock market prices future potential (high expectations for hundreds of millions of NOK in annual revenue at full operation). Private initiative from Scatec-inspired owners. Critical aspects (interventionist deviations): • State funding: The Innovasjon Norge loan is typical industrial policy Mises criticized – subsidizes risk, distorts capital allocation, and can lead to malinvestment financed by taxpayers. • Regulation: Heavy nuclear/pharmaceutical regulation (DSA, GMP) raises barriers and costs, replaces market assessment with bureaucracy. • Healthcare: Third-party payers (public reimbursement) distort demand further down the chain. Conclusion: Thor Medical exemplifies Misesian entrepreneurship in a distorted market – innovative, market-oriented, and potentially value-creating. Success depends on whether real profit from customers confirms economic sustainability without persistent state support. In a pure laissez-faire system (minimal state, sound money), such innovation would have flourished faster. The company is promising, but affected by interventionism which makes pure calculation more difficult.Ludwig von Mises is spinning so fast in his grave that he will soon produce electricity for A1 at Herøya....
- ·1 päivä sittenSecurities funds KLP and Storebrand Indeks have started gradually buying up. Perhaps there will be a little better development for the Thor share going forward?Yes it is small, based on the volumes that are currently trading. Where do you find info about this`?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
124 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenMy assessment, but no investment recommendation. 1. Start of production A1 shortly (at the latest by the end of Q3). Share price increase 2. New contracts are coming and potential extensions of existing ones. Customers report good Phase 2 results. 2026-2027. Share price increase 3. Plans for A2 and AGlobal will be launched with partners in USA and Asia. At the same time, customers are nearing completion of Phase 3 studies and approved treatments. 2027-2029. Share price increase 4. Thor has become an international stable supplier of isotopes for first-class cancer treatment for a range of cancer diseases. 2030. Stable dividend machine with good return.I actually think exactly the same. That's how I see it too. Good summary of a possible future.
- ·22 t sittenAssessment of Thor Medical ASA based on Ludwig von Mises’ economic principles: Thor Medical ASA (TRMED.OL) is a Norwegian listed company that produces alpha particle emitters (Th-228, Ra-224, Pb-212) for targeted cancer therapy. The technology utilizes natural thorium decay without reactors/cyclotrons with high efficiency, lower costs, and a better environmental profile than current players. Pilot production at Herøya since 2024; AlphaOne facility under construction (operation 2026). Several supply agreements (order book ~850 mill. NOK). 2025: Revenue ~0.8 mill. NOK, loss ~58 mill. NOK, cash ~181 mill. NOK, financed mainly via equity + drawn NOK 90 mill. loan from Innovasjon Norge. Strong management with pharma, industry, and nuclear expertise.  Mises’ core principles (Human Action et al.): Methodological individualism, subjective value, entrepreneurship under uncertainty, profit/loss as signals, voluntary exchange, private property – against state intervention, regulation, and artificial credit that distorts prices and creates malinvestment such as e.g. Morrow Batteries. Positive aspects (good correspondence): • Entrepreneurship: Classic discovery of opportunity – new separation technology solves isotope bottleneck in growing TAT market. Patents applied for (Mises supported IP protection for innovation). • Market mechanism: Voluntary contracts with private customers (Telix, ARTBIO et al.) show consumer sovereignty and value creation via prices. • Profit motive: Goal of profitable scaling; the stock market prices future potential (high expectations for hundreds of millions of NOK in annual revenue at full operation). Private initiative from Scatec-inspired owners. Critical aspects (interventionist deviations): • State funding: The Innovasjon Norge loan is typical industrial policy Mises criticized – subsidizes risk, distorts capital allocation, and can lead to malinvestment financed by taxpayers. • Regulation: Heavy nuclear/pharmaceutical regulation (DSA, GMP) raises barriers and costs, replaces market assessment with bureaucracy. • Healthcare: Third-party payers (public reimbursement) distort demand further down the chain. Conclusion: Thor Medical exemplifies Misesian entrepreneurship in a distorted market – innovative, market-oriented, and potentially value-creating. Success depends on whether real profit from customers confirms economic sustainability without persistent state support. In a pure laissez-faire system (minimal state, sound money), such innovation would have flourished faster. The company is promising, but affected by interventionism which makes pure calculation more difficult.Ludwig von Mises is spinning so fast in his grave that he will soon produce electricity for A1 at Herøya....
- ·1 päivä sittenSecurities funds KLP and Storebrand Indeks have started gradually buying up. Perhaps there will be a little better development for the Thor share going forward?Yes it is small, based on the volumes that are currently trading. Where do you find info about this`?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt